July 10, 2025 7:56am

Another econ, Initial Jobless Claims; economists are expecting an increase of 2,000 to 235,000 from the previous week

“Uncle algo and his electronic trading dwarfs” are hovering, drooling in anticipation and direction

Pre-Open Signals: 4 Positive and 1 Negative Indications

Never leave an investor uninformed …

I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: Riding the wave … https://www.regmedinvestors.com/articles/13990

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Thursday: The pre-open Dow futures are DOWN -0.02% or (-7 points), the S&P futures are UP +0.04% or (+3 points) and the Nasdaq futures are UP +0.08% or (+18 point)

  • Stock futures are mixed and flutuating i.e., “barely” moving on Thursday, 7/10
  • European markets opened higher,
  • Asia-Pacific markets traded mixed.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed UP +217.54 points or +0.49%, the S&P closed UP +37.74 points or +0.61% while the Nasdaq closed UP +192.87 points or +0.95%
  • Tuesday: The Dow closed DOWN -165.60 points or -0.37%, the S&P closed DOWN -4.46 points or -0.07% while the Nasdaq closed UP +5.95 points or +0.03%
  • Monday: The Dow closed points or DOWN -422.17 points or -0.94%, the S&P closed DOWN – 49.37points or -0.79% while the Nasdaq closed DOWN -188.59 points or -0.92%

Economic Data Docket: Initial Jobless Claims ending 7/5

 

Q3 – July – 1 market holiday, 5 positive and 1 negative closes

Q2  

  • June – 1 market holiday, 1 neutral, 8 negative, and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Yet again, I am passing on forecasting the daily indications due to the effects of jobless claims, vacation and newest highs after a pillage (Monday) of share pricing … it is still a mix of ups, downs and just uncertainty

Although:

CRISPR Therapeutics (CRSP) closed up +$5.26 after Tuesday’s +$3.62 after Monday’s -$0.98 with a positive +$5.78 or +0.95% pre-open

Lenz Therapeutics (LENZ) closed up +$3.46 after Tuesday’s -$0.12 after Monday’s -$1.11 with a positive +$0.50 or +1.44% pre-open

Ultragenyx Pharmaceuticals (RARE) closed up +$2.00 after Tuesday’s -$0.19 with a negative -$9.19 or -22.18% pre-open

Beam Therapeutics (BEAM) closed up +$1.17 after Tuesday’s +$1.11 after Monday’s -$0.83 with a positive +$1.22 or +5.69% pre-open

Intellia Therapeutics (NTLA) closed up +$1.02 after Tuesday’s+$0.87 after Monday’s -$0.49 with a positive +$0.19 or +1.57% pre-open

 

The BOTTOM LINE: July is here and summer doldrums and vacations and selling before the earnings cycle to pay for the lobster rolls.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Cell and gene therapy sector equities on Wednesday continued the run to the upside after Tuesday positive close after diving on Monday ….

  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

To characterize July, to understand the “flow” of markets, the cell and gene therapy sector and economic karma…

  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats
  • 7/4 – Friday was a market holiday
  • 7/3 – Thursday closed positive with 23 positive, 6 negative and 6 flats
  • 7/2 - Wednesday closed positive with 24 positive, 7 negative and 4 flats
  • 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, I brace myself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.